Exp Clin Endocrinol Diabetes 1997; 105(4): 234-236
DOI: 10.1055/s-0029-1211758
Case Report

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Apoplexy of a pituitary macroadenoma as a severe complication of preoperative thyrotropin-releasing hormone (TRH) testing

I. Szabolcs1 , N. Késmárki* , K. Bor2 , S. Czirják3 , O. Dohán1 , F. Slovik3 , M. Góth1 , L. Kovács1 , A. Ferencz4 , É. Rimanóczy4 , G. Szilágyi1
  • 1Division of Endocrinology, 1st Department of Medicine
  • 2Department of Radiology
  • 3Central Institute of Neurosurgery, Budapest
  • 4Department of Laboratory Investigations, Haynal Imre University of Health Sciences, Budapest
  • * research fellow from Nagykanizsa Hospital, Hungary
Further Information

Publication History

Publication Date:
14 July 2009 (online)

Summary

The case history of a 54-year-old male suffering from pituitary macroadenoma with suprasellar extension is reported. A TRH-test with 200 μg i.v. was followed by severe headache and vomiting after 60', and by development of ophthalmoplegia on the following day Hyperdens patches on the CT scan showed haemorrhage into the tumor. A chromophobic adenoma with macroscopic and histological signs of haemorrhage was removed via the transsphenoidal route. In the postoperative period the ophthalmoplegia gradually disappeared but central hypoadrenia and hypothyroidism occurred.

This is the second case in the literature showing that TRH alone and in a low dose may cause pituitary tumor apoplexy. It is concluded that TRH-testing is a risk for the patient with pituitary apoplexy If, due to the size of the tumor the patients have to be operated on in any case, and the test is not of essential diagnostic value, the TRH-test should be done only in selected cases. Its use in the post-operative evaluation however is without risk for the patients.